Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2026
Pharma News, 2026
Tufts Study: Sponsors and CROs Must Address Execution Translation Gap
A Tufts study highlights the execution translation gap in clinical trials, revealing rising protocol deviations and enrollment challenges for sponsors and CROs.
Barrow and ASU Launch First US Clinical Trials of Ibogaine for PTSD Care
Barrow Neurological Institute and ASU launch a $5M clinical trial to evaluate the safety and efficacy of ibogaine for treating PTSD, depression, and addiction.
FDA Accepts GSK's Jemperli for Priority Review in Advanced Rectal Cancer
The US FDA grants priority review to GSK's Jemperli for untreated dMMR/MSI-H locally advanced rectal cancer, potentially replacing chemo and surgery.
Carterra HT-SPR Platforms Support Anthropic AI-Designed Protein Study
Carterra's high-throughput SPR platforms validate Anthropic's AI-designed protein binders, accelerating drug discovery and overcoming validation bottlenecks.
Teva Bids $125M for BioXcel Therapeutics' Neuroscience Assets & Igalmi
Teva Pharmaceuticals bids $125M to acquire BioXcel Therapeutics' neuroscience assets, including Igalmi and BXCL501, expanding its strategic portfolio.
Kazia Therapeutics Paxalisib Achieves 100% Clinical Benefit Rate in TNBC
Kazia Therapeutics reports a 100% clinical benefit rate for its PI3K/Akt/mTOR inhibitor paxalisib in stage IV triple-negative breast cancer patients.
FDA Approves Protagonist Therapeutics' Mimrylo for Rare Blood Cancer Care
The FDA has approved Mimrylo (rusfertide) for treating polycythemia vera, offering a novel hepcidin-mimicking therapy to control red blood cell levels.
FDA Approves ViiV Healthcare’s Tivicay PD for Pediatric HIV-1 Treatment
ViiV Healthcare secured FDA approval for Tivicay PD to treat pediatric HIV-1 patients weighing at least 2kg, expanding crucial antiretroviral care options.
AusperBio Secures $120M Funding to Advance Chronic Hepatitis B Therapies
AusperBio raised $120 million in Series C funding to progress its chronic hepatitis B pipeline, including the Phase III trial for AHB-137 and AHB-171.
Novartis Pacibekitug Reduces Inflammation in Phase 2 Cardiovascular Trial
Novartis' pacibekitug showed sustained reductions in inflammation biomarkers in the Phase II TRANQUILITY study, highlighting cardiovascular disease benefits.
Prilenia Initiates PRECISE-HD Phase 3 Trial for Huntington's Disease Therapy
The first participant has been dosed in the PRECISE-HD Phase 3 trial evaluating pridopidine for early- to mid-stage Huntington’s disease patients.
FDA Approves Lisraya as First Oral Dermatomyositis Treatment for Adults
The FDA approved Priovant Therapeutics' Lisraya (brepocitinib) as the first oral treatment option for adult patients with the rare disease dermatomyositis.
2
3
4
5
6
7
8
9
10
